Molecular Partners AG (XSWX:MOLN) Total Stockholders Equity : CHF176.43 Mil (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Molecular Partners AG Total Stockholders Equity?

Molecular Partners AG's Total Stockholders Equity for the quarter that ended in Dec. 2023 was CHF176.43 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Molecular Partners AG's Book Value per Share for the quarter that ended in Dec. 2023 was CHF5.37. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Molecular Partners AG's Debt-to-Equity for the quarter that ended in Dec. 2023 was 0.02.

Molecular Partners AG Total Stockholders Equity Historical Data

The historical data trend for Molecular Partners AG's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Molecular Partners AG Total Stockholders Equity Chart

Molecular Partners AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

54.14

107.22

107.29

235.17

176.43

Molecular Partners AG Quarterly Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Stockholders Equity	Get a 7-Day Free Trial															235.17	222.16	205.98	196.21	176.43

Molecular Partners AG (XSWX:MOLN) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Molecular Partners AG's Book Value per Share for the quarter that ended in Dec. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(176.429	-	0)	/	32.8543
	=	5.37

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Molecular Partners AG's Debt-to-Equity for the quarter that ended in Dec. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.208	+	2.444)	/	176.429
	=	0.02

Molecular Partners AG Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Molecular Partners AG's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Molecular Partners AG (XSWX:MOLN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Partners AG (XSWX:MOLN) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

MOLN:USA MLLCF:USA MOLNz:UK 6ML0:Germany

Address

Wagistrasse 14, Schlieren, Zurich, CHE, 8952

Website

https://www.molecularpartners.com

Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.